EP4051381A1 - Compositions pour la réduction du risque cardiovasculaire - Google Patents

Compositions pour la réduction du risque cardiovasculaire

Info

Publication number
EP4051381A1
EP4051381A1 EP20811722.6A EP20811722A EP4051381A1 EP 4051381 A1 EP4051381 A1 EP 4051381A1 EP 20811722 A EP20811722 A EP 20811722A EP 4051381 A1 EP4051381 A1 EP 4051381A1
Authority
EP
European Patent Office
Prior art keywords
extract
plant belonging
association
genus
olea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20811722.6A
Other languages
German (de)
English (en)
Inventor
Umberto DI MAIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neilos SRL
Original Assignee
Neilos SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neilos SRL filed Critical Neilos SRL
Publication of EP4051381A1 publication Critical patent/EP4051381A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • compositions for oral use comprising at least an extract of red yeast rice, at least an extract of a plant belonging to the genus Olea and at least an extract of a plant belonging to the genus Malus and to the use thereof for the prevention and/or treatment of hypercholesterolemia, the main cardiovascular risk factor.
  • Hypercholesterolemia is a pathological condition characterized by the presence of high levels of lipids (such as cholesterol, triglycerides or phospholipids) in the bloodstream. It is considered the main atherosclerotic and cardiovascular risk factor since the excessive increase in the levels of LDL cholesterol has been associated to a greater coronary risk. Therefore, the reduction in the LDL levels seems to be the best approach to be adopted for the prevention of cardiovascular disorders.
  • the forms of familiar hypercholesterolemia (FH) are characterized by hyperproduction of cholesterol at hepatic level genetically determined and due, in most cases, to a mutation of the gene which codifies for the cell receptor of LDLs which, consequently, does not succeed anymore to bind the circulating LDL particles nor to remove them from the bloodstream.
  • dyslipidaemias very often are a consequence of the so-called metabolic syndrome and then attributable to an unhealthy lifestyle and/or eating habits.
  • This last type of dyslipidaemia is characterized, apart from high levels of LDL and low levels of HDL, also by obesity, insulin- resistance, hypertension and diabetes of type 2.
  • Epidemiological studies have further highlighted the involvement of other factors such as the plasmatic increase in fibrinogen and coagulation factors, the increase in the platelet activation and modifications of the oxidative state of LDLs.
  • the drug treatment of choice for the control of dyslipidaemias consists in the administration of statins alone or in association with other active principles as inhibitors of the absorption of cholesterol or inhibitors of PCSK9, an enzyme which regulates the degradation of the LDL receptors.
  • statins have considerable limits due to the serious side effects at the muscle and hepatic level (for example, myopathies, rhabdomyolysis, alteration of hepatic functionality and increase in transaminases) and to drug-resistance and intolerance phenomena.
  • statins In case of patients resistant to statins an inadequate (or lack in) reduction in the levels of LDL cholesterol occurs, accompanied by the appearance of the side effects, generally due to polymorphism of HMGCo-A reductase, of glycoprotein P, of cholesterol 7 a-hydroxylase, of apolipoprotein E, of lipoprotein A or of LDL receptor whereas, in the intolerant patients, the use of statins is absolutely not recommended since the side effects appear suddenly and in their most serious form.
  • Another factor to be considered is the fact that the treatment with statins is suitable for patients having high or very high cardiovascular risk and not for subjects having mild or moderate cardiovascular risk and they have LDL levels not far from the standard, thereto generally a simple lifestyle change is recommended. Therefore, there is still the need for solutions for the prevention and/or treatment of cholesterolemia and, more generally, for the control of cardiovascular risk in subjects resistant or intolerant to statins or who have a low or moderate cardiovascular risk factor.
  • the present invention is based upon the research and identification of a combination of natural substances which, when used in association, exert an effective and potentiated action in the prevention and/or treatment of hypercholesterolemia and then which is useful for the cardiovascular risk reduction.
  • the present invention relates to an association of at least an extract of red yeast rice, at least an extract of a plant belonging to the genus Olea and at least an extract of a plant belonging to the genus Malus.
  • the present invention also relates to compositions, preferably for oral use, comprising the association of at least an extract of red yeast rice, at least an extract of a plant belonging to the genus Olea, at least an extract of a plant belonging to the genus Malus and one or more suitable excipients and moreover a kit of portions comprising the above-mentioned active principles separated and formulated in suitable form of oral dosage for sequential or contemporary administration of the different active principles.
  • the present invention further relates to the use of said association, compositions and kit in the prevention and/or treatment of hypercholesterolemia, first cardiovascular risk factor, and also in the prevention and/or treatment of cardiovascular diseases such as atherosclerosis, coronary heart diseases, metabolic syndrome, stroke, predisposition to diabetes and obesity.
  • the composition the present invention relates to allows to obtain at the same time: ⁇ a reduction in hypercholesterolemia;
  • any product tracing back to a vegetable drug is meant, including all products deriving from mechanical treatment (pulverization, grinding, mixing and/or other methods) or from extractive treatments (extraction with solvent, distillation, and/or other specific methods) performed on a drug.
  • the present invention relates to an association comprising as main active principles at least an extract of red yeast rice, at least an extract of a plant belonging to the genus Olea and at least an extract of a plant belonging to the genus Malus.
  • the red yeast rice is a nutraceutical obtained from the fermentation of the white rice with the yeast Monascus purpureus responsible for the typical colour and the production of important secondary metabolites.
  • the so-enriched rice includes a series of bioactive compounds, thereamong sterols, isoflavones, unsaturated fatty acids and monacolins.
  • monacolins monacolin k is the most abundant and interesting. It is also known as lovastatin since the two molecules have an almost analogous structure.
  • monacolin k is present both in lactone form and in hydrolysed form. Generally, at low pH values the lactone form prevails which converts spontaneously into the active form of hydroxy acid at neutral or basic pH.
  • Monacolin k represents the active responsible for the health effect which the red yeast rice has on hypercholesterolemia. Thanks to its structural features, the above-mentioned molecule, as well as the statins, is capable of inhibiting the hydroxymethylglutaryl-CoA reductase (HMGCo-A reductase) enzyme which converts hydroxymethylglutaryl-CoA into Mevalonate and which represents the limiting enzyme in the cholesterol biosynthesis process.
  • HMGCo-A reductase hydroxymethylglutaryl-CoA reductase
  • statins The main side effects caused by the statins are due to the fact that the pharmacological treatment with the same causes the depletion of important metabolites such as Mevalonate, mitochondrial coenzyme Q and the regulatory proteins binding GTP, with consequences on the cellular energy metabolism, the mitochondrial function and the pathways of intracellular protein signalling.
  • important metabolites such as Mevalonate, mitochondrial coenzyme Q and the regulatory proteins binding GTP
  • the treatment with red rice results to be particularly advantageous since monacolin, even if it exerts the same action of the statins on the HMGCo-A reductase enzyme, has a markedly lower effect as far as the depletion of the cellular metabolites is concerned.
  • EFSA officially declared that there is a cause- effect relationship between the consumption of 10 mg/die of monacolin and the reduction in the level of LDL cholesterol in blood. This value was determined by considering two double-blind randomized studies, controlled with placebo, in which a reduction in the levels of total cholesterol and LDL cholesterol of 16% and 22%, respectively, is observed by administrating 7.5 mg/die of active principle for 12 weeks and a reduction in the above- mentioned outcomes of 20% and 26%, respectively, is observed by administering a dose containing 11.4 mg/die of monacolin for 8 weeks.
  • mice C57BL/6JApoe _/_ were divided into three groups: 1. Mice with normal diet, without treatment;
  • mice of group 2 not treated and subjected to a high-fat diet, developed atherosclerotic plaques and high levels of total cholesterol and LDL cholesterol with respect to the group fed with a normal diet.
  • the treatment with the extract reduced the sizes of the plaques by about 15% and the lesion area.
  • results obtained in the treated group highlighted a reduction in the plasmatic levels of cholesterol with respect to the control group and to the not treated group.
  • the treatment with the red rice extract reduced the levels of expression of HMGCoA reductase at hepatic level
  • RYR reduced the levels of expression, at aorta level, of TRL2, TRL4 and MAPK, pro-inflammatory proteins responsible for the activation of the cascades of signalling the inflammation and activation of some atherosclerotic genes;
  • the extract increased the levels of expression of JAM-1 and of occludins at intestinal level, by demonstrating to improve the intestinal functions of the mice Apoe _/_ and, then, to reduce the inflammation risk.
  • Monascus purpureus was tested in a great randomized, multicentric, double-blind study, controlled with placebo, performed on 4870 Chinese patients between 18 and 70 years old with a preceding documented myocardial infarction, with high levels of creatin kinase and with a medium level of LDL equal to 129 mg/dL.
  • the subjects were kept under control for a period of about 4 years and a half and it was evaluated: the appearance of coronary events, the mortality for cardiovascular problems and the levels of plasmatic lipids.
  • the results extrapolated from this study showed that in the subjects of the treated group there was a reduction in the levels of LDL cholesterol of about 20% with respect to placebo.
  • the total lipidic profile of the patients results to have improved, with a reduction in the levels of triglycerides and an increase in HDL cholesterol.
  • a reduction in the incidence of cardiovascular events and, more generally, of the mortality attributable to cardiovascular problems was noticed. The study did not notice any case of serious side effects.
  • a meta-analysis grouped 20 randomized trials with 6653 participants.
  • Olea Europaea commonly defined olive tree, is an evergreen fruit tree belonging to the family of Oleaceae. It is very long-lived, it may become millennial and reach heights of 15 - 20 meters. It is one of the most ancient trees cultivated in the Mediterranean region and since antient times it has been used in the food sector. Its fruits, olives, are used for extracting olive oil whereas the standardized extracts of leaves are used for medical purposes for the lipid-lowering, vasodilating, hypotensive and anti-inflammatory properties. A large number of scientific evidence highlights the role of Olea Europaea in the prevention and management of several diseases, including those at cardiovascular level.
  • Olea includes flavonoids, flavonic glycosides, flavonones, iridoids, secoiridoids, triterpenes, biophenols, derivatives of the benzoic acid, sterols and xylitols.
  • the phenolic compound oleuropein is considered the main responsible of the characteristic therapeutic effects and several studies showed that oleuropein is effective as antioxidant, anti-inflammatory, anti-atherogenic, anti-cancer, antimicrobial and antiviral agent.
  • Olea Europea is considered a valid natural remedy for controlling hypercholesterolemia and for reducing the atherosclerotic risk.
  • Group 2 SCD diet and treatment with Atorvastatin 20 mg/kg
  • Group 3 SCD diet and treatment with Olea extract 50 mg/kg
  • Group 4 SCD diet and treatment with Olea extract
  • Group 5 rats subjected to high-fat diet (HCD);
  • Group 6 HCD diet and treatment with Atorvastatin 20 mg/kg;
  • Group 7 HCD diet and treatment with Olea extract 50 mg/kg;
  • Group 8 HCD diet and treatment with Olea extract
  • the lipidic profile of animals was analysed.
  • a worsening of the total lipidic profile is noted, with an increase in cholesterol and LDL.
  • the plasmatic levels of lipids have decreased significantly with both used concentrations.
  • the levels of the antioxidant enzymes and the markers of lipidic peroxidation were measured.
  • the rats with HCD diet showed a huge increase in atherosclerotic index. Such effect is reversed after the treatment with the extracts.
  • Annurca Malus pumila var. Annurca is the only apple variety native to Southern Italy, mainly in the region Campania between Caserta and Benevento. Annurca apple has a pulp rich in juice, a compact, crunchy pulp and characterized by the typical sour taste which distinguished it from other apple varieties. Healthy properties have always been attributed to apple.
  • the benefits brought by the consumption of apples can be attributed to the polyphenolic content of the fruit constituted by quercetin, epicatechin, catechin, procyanidins, anthocyanins, dihydrochalcones and phenolic acids. Even if the components are substantially the same, the specific amounts vary among the different apple varieties.
  • the polyphenols can be present under form of dimers, trimers, tetramers, pentamers and oligomers having high molecular weight.
  • the polyphenolic fraction is above all rich in procyanidins, in particular procyanidin B2, and oligomers formed by a number of monomers comprised between 6 and 8.
  • the apple extract is known having chemoprotective properties.
  • the hypolipidemic effect can be mainly attributed to procyanidins and this makes the polyphenolic extract of Annurca very promising in this field.
  • the complex action mechanism of polyphenols of Annurca apple was brought to light by several in- vitro studies.
  • the beneficial effect on hypercholesterolemia is due to the combined action of dimeric procyanidins (in particular procyanidin B2) and of oligomers. Both these fractions of Annurca polyphenolic complex are responsible for the hypolipidemic effect, but with different action mechanisms.
  • the several performed pre- clinical studies, in particular the studies on bioavailability and bioaccessibility of the polyphenols of Annurca apple confirm the hypothesis according thereto the oligomers having high molecular weight are not absorbed at intestinal level.
  • oligomers accumulate in the intestine and act here locally to reduce the levels of cholesterol by acting in a way similar to b-cyclodextrins and forming complexes similar to micelles incorporating cholesterol and preventing the absorption thereof.
  • dimers are quickly absorbed in the intestinal tract and reach quickly liver wherein, indirectly, they are involved in the increase in the LDL receptors. Therefore, the dimeric procyanidins are capable of reducing the levels of LDL cholesterol with the same effectiveness of statins and, differently from the latter which have no effect on HDL, form stable complexes with apolipoprotein Al, main protein structural component of HDLs, and increase the inverted route of cholesterol and, consequently, the levels of eliminated cholesterol.
  • a preliminary clinical study performed on 250 patients with a moderate hypercholesterolemia evaluated the effect that the ingestion of two Annurca apples per day exerts on the lipidic profile of the considered subjects compared to that of other apple varieties.
  • the results of the study demonstrated that, with respect to other highlighted apple varieties, Annurca apple is responsible for a significative reduction in the levels of total cholesterol and LDL cholesterol and the increase in the levels of HDL.
  • a monocentric, double-blind, clinical study was prepared, controlled with placebo, lasting 16 weeks on 250 subjects with mild and moderate hyperlipidaemia.
  • the subjects selected for the study (116 men and 134 women) were aged between 30 and 83 and had the following basal levels of cholesterol: total cholesterol 214 - 254 mg/dL; LDL cholesterol 150 - 205 mg/dL; HDL cholesterol 30 - 43 mg/dL.
  • the participants in the study were subjected to a first study phase of 4 weeks, in which a placebo was administered, followed by phase two of 8 weeks, in which two capsules per day of polyphenolic extract of Annurca apple containing each one 400 mg were administered, to finish with 4 weeks of follow-up.
  • the present invention relates to an association of at least an extract of red yeast rice, at least an extract of a plant belonging to the genus Olea and at least an extract of a plant belonging to the genus Malus.
  • the composition can include at least one, two, three or more extracts of red yeast rice.
  • red rice extract the rice yeast product inoculated with the red yeast, Monascus purpureus is designated.
  • the red yeast rice can be any extract preferably titrated at a certain percentage of monacolin k.
  • extracts of red yeast rice having a titre in total monacolin K (acid form plus lactone form) of at least 0.1%, preferably of about 0.3 to about 10% can be used.
  • an extract of red yeast rice suitable to the implementation of the present invention can have a titre in monacolin k from 0.5% to 5%.
  • the authors of the invention showed that amounts comprised between 1 and 10000 mg per day of extract of red yeast rice in combination to at least an extract of a plant belonging to the genus Olea and at least an extract of a plant belonging to the genus Malus as herein described are effective, by obtaining the reduction in plasmatic cholesterol in the treated subjects.
  • 1 capsule/die comprising 333.3 mg of extract of red yeast rice titrated at 3% in monacolin K, corresponding to about 10 mg of monacolin K per capsule, for a total of 10 mg/die, can be administered.
  • the composition includes at least an extract of Olea europaea.
  • the extract could be prepared according to the procedures known in the state of art, for example it could be a dry extract of the leaves titrated in polyphenols.
  • the extract of Olea europaea for example, will be prepared by means of extraction in a mixture of ethanol/water.
  • the extract of Olea europaea for example could be administered with a dosage regime comprised between 1 and 10000 mg/die, in particular between 10 and 2000 mg/die.
  • the composition can comprise at least one, two or more extracts selected among Malus pumila or Malus domestica var. Annurca, preferably Malus pumila cultivar Annurca.
  • the extract could be prepared according to the procedures known in the state of art, for example it could be a dry extract of Malus pumila having high content in polyphenols.
  • the extract for example, could be prepared by means of extraction in water of the fruit and optionally lyophilized.
  • the apple extract in particular di Malus pumila var.
  • annurca could be administered for example with a dosage regime comprised between 1 and 10000 mg/die, in particular between 10 and 3000 mg/die, preferably in 1-2 separate administrations (for example 400 mg x 2 times per day, or 400 mg once a day).
  • the person skilled in the art could adapt the amount of extract used in the preparation of the formulations to be administered according to the used extract of red yeast rice, Olea and Malus.
  • the general practitioner will be able to identify the optimum dosage for the subject to be treated based upon age, sex, weight and general health state. Therefore, the dosage of the single active principles can be adapted, even during the period of assumption of the association or composition of the invention according to the results obtained over time.
  • the inventors have detected the optimal pro dose dosages (or per single dosage unit) of each extract.
  • the pro dose dosage of extract of red yeast rice is comprised between 1 mg and 10000 mg, preferably between 10 mg and 3000 mg, still more preferably between 20 mg and 2000 mg.
  • the pro dose dosage of extract of plant belonging to the genus Olea is comprised between 1 mg and 10000 mg, preferably between 10 mg and 2000 mg, still more preferably between 20 mg and 1000 mg.
  • the pro dose dosage of extract of plant belonging to the genus Malus is comprised between 1 mg and 10000 mg, preferably between 10 mg and 3000 mg, still more preferably between 20 mg and 2000 mg.
  • the extract of red yeast rice is present in an amount comprised between 1 mg and 10000 mg, preferably between 10 mg and 3000 mg, still more preferably between 20 mg and 2000 mg per dosage unit;
  • the extract of plant belonging to the genus Olea is present in an amount comprised between 1 mg and 10000 mg, preferably between 10 mg and 2000 mg, still more preferably between 20 mg and 1000 mg per dosage unit;
  • the extract of plant belonging to the genus Malus is present in an amount comprised between 1 mg and 10000 mg, preferably between 10 mg and 3000 mg, still more preferably between 20 mg and 2000 mg per dosage unit.
  • the association of the present invention could include one or more extracts of each one of the herein described active principles, provided that it comprises at least an extract of red yeast rice, at least an extract of a plant belonging to the genus Olea and at least an extract of a plant belonging to the genus Malus.
  • the association comprises extract of red yeast rice, extract of Olea europaea and extract of Malus pumila var. annurca.
  • the present invention further relates to compositions comprising the association according to any one of the herein described embodiments and to one or more suitable excipients.
  • the composition comprises, as main active ingredients, extract of red yeast rice, extract of Olea europaea and extract of Malus pumila var. annurca and one or more excipients as defined hereinafter.
  • the composition comprises at least an extract of red yeast rice, at least an extract of a plant belonging to the genus Olea and at least an extract of a plant belonging to the genus Malus as single active principles in reducing hematic cholesterol and/or cardiovascular risk.
  • composition can comprise other components, such as for example excipients, carriers, stabilizers, preserving agents and the like and/or other active principles, provided that said other active principles are not indicated in the reduction in the plasmatic cholesterol and/or cardiovascular risk in general.
  • compositions according to any one of the embodiments provided in the present description can be formulated in any form and by any administration route and associated to any other component, in a variety of ways.
  • compositions of the invention are compositions for oral use in solid form such as, for example, powder, orodispersible powder, granulate, hard capsule or soft-gel, tablet, sachet, pill or gelatine or in liquid form such as, for example, emulsions, solutions, prepared or extemporaneous suspensions, syrups and elixirs.
  • Suitable excipients can be selected among those usually known in the state of art and include, but they are not limited thereto: diluents (for example dibasic calcium phosphate, lactose, microcrystalline cellulose and cellulose derivatives), thickeners (for example gums, hydroxypropyl methylcellulose and other cellulose derivatives), sweeteners (for example sorbitols, mannitol and other polyols, acesulfame K, aspartame, cyclamates, saccharin, sucralose), lubricants (for example magnesium stearate, stearic acid, waxes), dispersants, surfactants (for example sodium lauryl sulphate and polysorbates), flavouring agents, adsorbents (for example silica gel, talcum, starch, bentonite, kaolin), glidants and anti-adhering agents (for example talcum, colloidal silica, corn starch, silicon dioxide), dyes (for example
  • solid dosage forms could be coated with enteric, gastric coatings or coatings of other type known in the state of art.
  • compositions of the present invention for example, will be a medical device, food supplement, a nutraceutical, dietetic or nutritional composition, foodstuff, a beverage, food, a nutraceutical, medicated food, food for special medical purposes, or a pharmaceutical composition.
  • the compositions of the present invention could further be, for example, simple feed, complementary feed, complete feed, feed intended to particular nutritional purposes or medicated feed.
  • compositions according to any one of the herein described embodiments could be used both by human beings and by animals.
  • the present invention also relates to a kit of portions including the different active principles of the association according to any one of the herein described embodiments separated and formulated in suitable oral dosage form for sequential or contemporary administration of the different active principles.
  • the present invention constitutes a valid support for the reduction in hypercholesterolemia, main cardiovascular risk factor, thanks to the combined and diversified action of its components.
  • the inventors came to the conclusion that the red yeast rice, rich in monacolin k, contributes to reduce the plasmatic levels of cholesterol by inhibiting the biosynthesis thereof at hepatic level and, at the same time, by reducing the phenomena of vascular oxidation; the compounds present in the olive extract potentiate the action of monacolin both at hepatic level and at vascular level and they contribute to increase the levels of HDLs; procyanidins of Annurca apple reduce the plasmatic levels of cholesterol by increasing the receptors of LDLs and by reducing the intestinal absorption thereof and, at the same time, they increase the levels of HDL.
  • the present invention further relates to the association, to the compositions and to the kit, according to any one of the herein described embodiments, for use in the treatment and/or in the prevention of hypercholesterolemia, both in humans and in animals.
  • the present invention also relates to the association, to the compositions and to the kit, according to any one of the herein described embodiments, for use in the prevention and/or in the treatment of disorders affecting the cardiovascular apparatus such as, for example, atherosclerosis, coronary heart diseases, metabolic syndrome, stroke, predisposition to diabetes and obesity, both in humans and in animals.
  • cardiovascular apparatus such as, for example, atherosclerosis, coronary heart diseases, metabolic syndrome, stroke, predisposition to diabetes and obesity, both in humans and in animals.
  • the association of the above-mentioned active principles could be formulated in one single composition or in a kit according to the various above-described embodiments and prepared for example by mixing the selected active principles with possible other excipients as it is known to the person skilled in the art.
  • the authors of the present invention have observed that the administration by oral route of a composition comprising the association of at least an extract of red yeast rice, at least an extract of a plant belonging to the genus Olea, in particular Olea europaea, and at least an extract of a plant belonging to the genus Malus, in particular, Malus pumila var. annurca results to be effective in the reduction in the plasmatic cholesterol and in the cardiovascular risk in general, also thanks to the synergic action of its components.
  • RNA extracted from the samples is subjected to specific treatments such as for example RT-PCR to evaluate the levels of expression of pro-inflammatory proteins such as for example IL-Ib, TNF-a and iNOS.
  • An in-vitro test to evaluate the levels of oxidative stress consists in treating the cells with specific agents such as for example 2,7- dichlorodihydrofluorescein acetate.
  • the generated fluorescence can be measured by means of fluorescence microscope at 529 nm.
  • Other methods conventionally known to the person skilled in the art can be used to evaluate the antioxidant activity of the formulation of the present invention. For example, it is possible to study the expression of SOD1 and NOX4 under conditions of stimulus induced by LPS or hyperglycaemia before and after treatment with the substances the present invention relates to.
  • an in-vitro test can be performed on a murine or human cell line.
  • the treated and not treated cells are incubated with marked cholesterol and, subsequently, washed to remove the excess.
  • the radioactivity of the solubilized cells is measured.
  • the composition of the present invention can involve a reduction in the uptake of cholesterol in a range from 1 to 80% with respect to the single ingredients.
  • the effectiveness of the present invention can be evaluated even by means of an in vivo test on experimental animals in line with the directives of the European Community and of the Ministry of Health and approved by an Ethics Committee.
  • mice ApoE which, after a period of acclimatation, are divided into groups and subjected to the treatment. At time zero and at established intervals, until the end of the treatment period, plasma samples are collected and the levels of total cholesterol, LDL cholesterol and HDL cholesterol are measured.
  • mice are sacrificed and samples of hepatic, intestinal and arterial tissue are collected.
  • the collected and lysed tissues are subjected to a western blot to evaluate the levels of some proteins of interest in particular, on the hepatic tissue the levels of HMG-CoA reductase and squalene monoxidase can be evaluated, on the arterial tissue the levels of pro-inflammatory proteins such as IL-Ib, TNF-a, TLR2, TLR4 and MAP-kinase can be evaluated and on the intestinal tissue the total functionality of the tissue of interest can be evaluated by evaluating the levels of junction proteins such as occludins or JAM-1.
  • any one of the herein described in-vitro or in vivo tests can be used.
  • the association of at least an extract of red yeast rice with at least an extract of a plant belonging to the genus Oiea and with at least an extract of a plant belonging to the genus Malus allows a reduction in the intestinal absorption of cholesterol/of plasmatic cholesterol significantly higher with respect to what is obtained with the administration of the single active principles or of only two active principles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions à usage oral comprenant au moins un extrait de riz de levure rouge, au moins un extrait d'une plante appartenant au genre Olea et au moins un extrait d'une plante appartenant au genre Malus et son utilisation pour la prévention et/ou le traitement de l'hypercholestérolémie, le facteur de risque cardiovasculaire principal.
EP20811722.6A 2019-10-29 2020-10-28 Compositions pour la réduction du risque cardiovasculaire Withdrawn EP4051381A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102019000019972A IT201900019972A1 (it) 2019-10-29 2019-10-29 Composizioni per la riduzione del rischio cardiovascolare
PCT/IB2020/060078 WO2021084428A1 (fr) 2019-10-29 2020-10-28 Compositions pour la réduction du risque cardiovasculaire

Publications (1)

Publication Number Publication Date
EP4051381A1 true EP4051381A1 (fr) 2022-09-07

Family

ID=69811585

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20811722.6A Withdrawn EP4051381A1 (fr) 2019-10-29 2020-10-28 Compositions pour la réduction du risque cardiovasculaire

Country Status (3)

Country Link
EP (1) EP4051381A1 (fr)
IT (1) IT201900019972A1 (fr)
WO (1) WO2021084428A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUB20150541A1 (it) * 2015-03-03 2016-09-03 Acraf Composizione comprendente sostanze e/o estratti naturali
IT201700025666A1 (it) * 2017-03-08 2018-09-08 Neilos S R L Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
WO2019197481A1 (fr) * 2018-04-13 2019-10-17 Ioulia Tseti Composition, sous forme d'une capsule molle, comprenant une combinaison d'extraits d'olive , de levure de riz rouge et de crocus sativus et procédé de préparation associé
EP3590356A1 (fr) * 2018-07-05 2020-01-08 Uriach Consumer Healthcare, S.L. Composition de contrôle et de réduction des niveaux de cholestérol dans le sang

Also Published As

Publication number Publication date
WO2021084428A1 (fr) 2021-05-06
IT201900019972A1 (it) 2021-04-29

Similar Documents

Publication Publication Date Title
US7887852B2 (en) Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US8492351B2 (en) Anti-cholesterolemic compounds and methods of use
ES2613381T3 (es) Nuevos extractos de Cynara scolymus, Coffea spp. y Olea Europaea para el tratamiento de síndrome metabólico
US20080254135A1 (en) Resveratrol-containing compositions for general health and vitality
JP4686173B2 (ja) ポリフェノールおよび／またはビタミンｃを含有するアセロラ処理物
Nemzer et al. Bioactive compounds, antioxidant activities, and health beneficial effects of selected commercial berry fruits: A review
WO2021079253A1 (fr) Composition pour la réduction du risque cardiovasculaire
NO324796B1 (no) Anvendelse av fosfolipidkomplekser ekstrahert fra Vitis vinifera ved fremstilling av antiaterosklerotiske midler.
US20030055103A1 (en) Utilization of achyrocline satureoides ("Marcela") extracts and liposomal preparations of natural and semi-synthetic flavonoids for the prevention and treatment of the consequences of stroke and neurodegenerative diseases
KR101350954B1 (ko) 아실-코에이:콜레스테롤 아실 트랜스퍼라제 저해 활성을가지는 조성물
US20220401505A1 (en) Composition for reducing cardiovascular risk
KR20170023910A (ko) 퀘르세틴-3-o-글루코시드를 포함하는 비알콜성 지방간 예방 또는 치료용 약학적 조성물
WO2008156627A1 (fr) Huiles riches en phytochimiques et procédés associés
KR20180025661A (ko) 콩 발아배아 추출물을 포함하는 여성 갱년기 질환의 예방 또는 치료용 약학조성물
JP2007254427A (ja) 抗酸化剤およびその用途
MXPA05002081A (es) Extractos mejorados de psidium huajava, metodos para su obtencion y su uso para el tratamiento de padecimientos gastrointestinales.
EP4051381A1 (fr) Compositions pour la réduction du risque cardiovasculaire
KR101246694B1 (ko) 초크베리 생물활성분획물 ｃ３ｇ 복합체를 유효성분으로 함유하는 동맥경화 및 고혈압 예방 및 치료용 약학적 조성물
CA2585010A1 (fr) Compositions contenant du resveratrol pour l'etat general de la sante et la vitalite
KR100640094B1 (ko) 콜레스테롤 저하 또는 항산화 활성을 갖는 녹차씨유를 포함하는 조성물
Singh et al. The phytochemistry and pharmacological activity of Terminalia arjuna (Roxb) Wight & Arn
US20180000776A1 (en) Formulation for the prevention and treatment of bone related disorders
JP2008513350A (ja) フラボノイドとトコトリエノールを含む組成物及びその方法
Ho et al. Crataegus (Hawthorn)
Ho et al. and Yu Huang Chinese University of Hong Kong Shatin, Hong Kong, China

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220526

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240501